Biosyntech
Laval · Founded 1994
About Biosyntech
BioSyntech, Inc. develops biotherapeutic thermogels designed for tissue repair and delivery of therapeutic agents. Its technology platform is BST-Gel, a family of hydrogels based on chitosan, a natural biopolymer derived from crustacean shells. The company’s lead products in clinical trials include BSTCarGel for cartilage repair; BST-DermOn for wound healing; and BST-InPod for the treatment of chronic pain due to plantar fat pad atrophy in the heel and forefoot. Biosyntech has a collaboration with Nicholas Piramal India, Ltd. to involve in the clinical studies for BST-InPod, which is being developed to alleviate the chronic pain associated with foot fat pads. The company was incorporated in 1994 and is headquartered in Laval, Canada.
Company Facts
- Founded: 1994
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $1.4M
- Last round: Series Unknown (Aug 2009)
- Website: http://www.biosyntech.com
- Phone: +1 450-686-2437
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/biosyntech-2900085 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.